Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5AP | P20292 | 19/20 | 0.65 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.65 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.65 |
| ▸ | PTGS1 | P23219 | 5/20 | 0.61 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5533195 | 0.92 | ALOX5AP (0.64) | ALOX5APCYP3A4CYP2C9PTGS1PTGS2 | |
| SCHEMBL5525705 | 0.90 | ALOX5AP (0.63) | ALOX5APCYP3A4CYP2C9PTGS1PTGS2 | |
| SCHEMBL5533113 | 0.90 | ALOX5AP (0.67) | ALOX5APCYP3A4CYP2C9PTGS1PTGS2 | |
| SCHEMBL5527876 | 0.90 | PTGS1 (0.78) | ALOX5APCYP3A4CYP2C9PTGS1PTGS2 | |
| SCHEMBL5528534 | 0.89 | ALOX5AP (0.69) | ALOX5APCYP3A4CYP2C9PTGS1PTGS2 | |
| SCHEMBL3468384 | 0.88 | ALOX5AP (0.84) | ALOX5APCYP3A4CYP2C9PTGS1 | |
| SCHEMBL5525476 | 0.84 | ALOX5AP (0.59) | ALOX5APCYP3A4CYP2C9PTGS1 | |
| SCHEMBL5527033 | 0.84 | ALOX5AP (0.68) | ALOX5APCYP3A4CYP2C9PTGS1 | |
| SCHEMBL5527808 | 0.83 | ALOX5AP (0.69) | ALOX5APCYP3A4CYP2C9PTGS1 | |
| SCHEMBL5530496 | 0.82 | PTGS1 (0.66) | ALOX5APCYP3A4CYP2C9PTGS1PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070219206-A1 | 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS | AMIRA PHARMACEUTICALS, INC. (US) | 2007-09-20 | — | — | US | claimed |
| US-20070219206-A1 | 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS | AMIRA PHARMACEUTICALS, INC. (US) | 2007-09-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070219206-A1 | 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS | ALOX5, ALOX15B, ALOX15 | ALOX5AP 4/4885CYP3A4 912/4885CYP2C9 2125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.